canyon landscape

A multicenter, open-label, extension trial to investigate long term efficacy and safety of lonapegsomatropin in adults with growth hormone deficiency.


This is a phase 3 open-label multicenter extension trial designed to evaluate the long-term safety and efficacy of lonapegsomatropin administered once-weekly. The trial participants are adults (males and females) with confirmed GHD having completed the treatment period in trial TCH-306 (foresiGHt).

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
Ascendis Pharma Endocrinology
Contact Us

Enrollment Information

Contact Nohemi Ramirez-Castillo at (602) 406-3231